权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Metabolic and epigenetic dependencies in melanomas during metastasis and targeted-drug resistance

黑色素瘤转移和靶向药物耐药过程中的代谢和表观遗传依赖性

基本信息

批准号：
10599853
负责人：
Pere Puigserver
金额：
$ 44.15万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10599853
关键词：
Acute Address Applications Grants Attenuated Automobile Driving BRAF gene Bioenergetics Biogenesis Blocking Antibodies Cell Line Cells Chromatin Chronic Clinical Clinical Management Data Dependence Disease Disease remission Drug Targeting Drug resistance EZH2 gene Ensure Enzymes Epigenetic Process Experimental Designs Failure Gene Expression Genetic Growth Heterogeneity Histones Human Immune system In Vitro Invaded Link Malignant Neoplasms Melanoma Cell Metabolic Metabolism Metastatic Melanoma Mitochondria Modeling Molecular Molecular Target Neoplasm Metastasis Oncogenes Oncogenic Outcome Study Patients Pattern Pharmaceutical Preparations Primary Lesion Process Promoter Regions Refractory Relapse Reporting Repression Resistance Role Site Skin Cancer Specimen Therapeutic Transcription Coactivator Treatment outcome Variant Vertical Growth Phase cancer cell clinical risk clinically relevant combinatorial established cell line expectation immune checkpoint in vivo melanoma patient prognosis promoter recruit response small molecule targeted treatment therapy resistant trait transcriptome treatment response tumor tumor behavior whole genome

项目摘要

Project Summary Metastatic melanoma was until recently considered an untreatable disease, but the discovery of small molecules that inhibit oncogenic BRAF(V600E) and approaches that unleash the immune system against tumors have brought hope to melanoma patients. Not every patient will have meaningful therapeutic benefit from these treatments and durable disease remission remains elusive for most. Among the causes of the failure to respond or early relapse is a dynamic cancer cell heterogeneity that facilitates outgrowth of therapy resistant tumors with enhanced malignancy traits. In order to extend the use of current therapies, we propose to identify alternative molecular targets that could be harnessed for combinatorial treatment exploit and might hold promise for sustainable therapeutic benefit. Specifically, whether metabolic and epigenetic processes provide collateral dependencies within highly metastatic and chronic BRAF-targeted drug-adapted melanomas is largely unknown. To this end, a third of melanomas display heightened expression of the transcriptional coactivator PGC1α that integrates mitochondrial biogenesis and bioenergetic activity to ensure cellular survival. Previously we found an inverse functional relationship between PGC1α expression and vertical growth phase within primary melanoma that associates with poor patient prognosis, and genetic targeting of PGC1α provoked enhanced metastatic traits in cell line models. Consistent with a functional role for adaptive expression of PGC1α and enhanced malignancy traits, our current preliminary data supports that chronic adaptation to BRAF-targeted drugs silences PGC1α expression through altered histone marks across its promoter region. We now propose to seek the molecular mechanisms that attenuate PGC1α expression that links enhanced metastatic spread and chronic adaptation to BRAF-targeted drugs. In an integrated study plan that includes clinical melanoma specimens, established cell lines and in vivo tumor modeling, the experimental design is focused on two aims: 1) to determine epigenetic mechanisms that silence PGC1α expression during chronic adaptation to targeted BRAF(V600E) treatment; and 2) to identify collateral metabolic and epigenetic vulnerabilities arising from chronic adaptation to targeted BRAF(V600E) treatment. Outcomes from these studies will identify metabolites and epigenetic regulators that provoke vulnerabilities within alternate PGC1α- dependent epigenetic states. Successful completion of the proposed study plan may help predict patients at heightened clinical risk as well as provide means to break chronic adaptation to BRAF-targeted drugs.

项目总结